Tamsulosin ? a new insight on a well-known medicine Review article
Article Sidebar
Published:
Jun 30, 2020
Keywords:
tamsulosin, ?1-adrenergic receptor antagonists, OCAS, treatment, benign prostatic hyperplasia, hypertension
Main Article Content
Abstract
After subsequent cardiac societies? guidelines definitely declassified the group of ?-blockers as drugs recommended for I line treatment, a successful therapy for patients with prostatic hyperplasia appeared to be a challenge. At that time, tamsulosin, due to its unique and highly selective mechanism of action against ?1-adrenergic receptors (found in prostate), proved to be a promising direction in terms of benign prostatic hyperplasia treatment. Clinical research results, together with the progress of pharmaceutical technology, allow to establish a promising, highly effective and, above all, safe therapy for patients diagnosed with prostatic hyperplasia.
Article Details
How to Cite
Jarosz-Popek , J., Czajka , P., & Postuła , M. (2020). Tamsulosin ? a new insight on a well-known medicine. Medycyna Faktow (J EBM), 13(2(47), 188-191. https://doi.org/10.24292/01.MF.0220.7
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. Moser M. Myths, misconceptions and heroics. The story of the treatment of hypertension form the 19309. Le Jacq Communications. Inc., Greenwich, Connecticut 1997: 1-68.
2. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986; 136: 1-4.
3. Insel PA. Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med. 1996; 344: 580-5.
4. Veelken R, Schmieder RE. Overview of a1-adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens. 1996; 9: 139S-49S.
5. Ejchman W. BPH-fitoterapia. Zalety i działania niepoża?dane. Prz Urol. 2004; 5(1): 26-7.
6. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995; 168: 7-12.
7. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Urticae radix. 2nd ed. Nortfolk. 2003: 528-35.
8. Weiss RF, Fintelmann V. Herbal Medicine. 2nd ed. Stuttgart ? New York 2000: 236-9.
9. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan Jr ED et al (ed). Campbell?s urology. 8th ed. Saunders, Filadelfia 2002: 1297-330.
10. Zdrojewski T, Bandosz P, Szpakowski P et al. Ocena wybranych problemów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL PLUS. In: Więcek A, Kokot F (ed). Postępy w nefrologii i nadciśnieniu tętniczym. Vol. 2. Medycyna Praktyczna, Kraków 2002: 11-5.
11. Tykarski A, Posadzy-Małaczyńska A, Wyrzykowski B et al. Rozpowszechnienie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ. Kardiol Pol. 2005; 63: 6(S4).
12. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000; 283: 1967-75.
13. Farmer R, Hutchison A, Chapple C. Comparison of the treatment regimens of new and existing LUTS/BPH patients in 6 European countries. Eur Urol Suppl. 2004; 3(2): 60 [Abstract 230].
14. Abrams P, Schulman CC. Vaage S, for the European Tamsulosin Study Group. Tamsulosin, a selective ?1C-adrenoceptor antagonist: a randomised, controlled trial in patients with benign prostatic ?obstruction? (symptomatic BPH). Br J Urol. 1995; 76: 325-36.
15. Lepor H; for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia. Placebo-controlled, double- blind extension of phase III trial. Urology. 1998; 51: 901-6.
16. Chapple CR, Wyndaele JJ, Nordling J et al. Tamsulosin, the first prostate-selective ?1A-adrenoceptor antagonist: a meta-analysis of two randomised, placebo-controlled, multi-centre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 1996; 29: 155-67.
17. Michel MC, Gru?bbel B, Taguchi K et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha-1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996; 16: 21-8.
18. Schwinn DA, Michelotti GA. ?1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the ?1D subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000; 85(suppl 2): 6-11.
19. Romic I, Kiss T, Kisbenedek L et al. Tamsulosin drug ratio in prostate versus free fraction in plasma supports pharmacokinetic (PK) contribution to its uroselectivity. J Urol. 2003; 169(4 suppl): 288 [Abstract 1118].
20. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin. An update of its role in the management of lower urinary tract symptoms. Drugs. 2002; 62: 135-67.
21. Michel MC, Korstanje C, Krauwinkel W. Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. Eur Urol Suppl. 2005; 4(2): 9-14.
22. Michel MC, Korstanje C, Krauwinkel W et al. Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation. Eur Urol Suppl. 2005; 4(2): 53-60.
2. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986; 136: 1-4.
3. Insel PA. Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med. 1996; 344: 580-5.
4. Veelken R, Schmieder RE. Overview of a1-adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens. 1996; 9: 139S-49S.
5. Ejchman W. BPH-fitoterapia. Zalety i działania niepoża?dane. Prz Urol. 2004; 5(1): 26-7.
6. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995; 168: 7-12.
7. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Urticae radix. 2nd ed. Nortfolk. 2003: 528-35.
8. Weiss RF, Fintelmann V. Herbal Medicine. 2nd ed. Stuttgart ? New York 2000: 236-9.
9. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan Jr ED et al (ed). Campbell?s urology. 8th ed. Saunders, Filadelfia 2002: 1297-330.
10. Zdrojewski T, Bandosz P, Szpakowski P et al. Ocena wybranych problemów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL PLUS. In: Więcek A, Kokot F (ed). Postępy w nefrologii i nadciśnieniu tętniczym. Vol. 2. Medycyna Praktyczna, Kraków 2002: 11-5.
11. Tykarski A, Posadzy-Małaczyńska A, Wyrzykowski B et al. Rozpowszechnienie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ. Kardiol Pol. 2005; 63: 6(S4).
12. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000; 283: 1967-75.
13. Farmer R, Hutchison A, Chapple C. Comparison of the treatment regimens of new and existing LUTS/BPH patients in 6 European countries. Eur Urol Suppl. 2004; 3(2): 60 [Abstract 230].
14. Abrams P, Schulman CC. Vaage S, for the European Tamsulosin Study Group. Tamsulosin, a selective ?1C-adrenoceptor antagonist: a randomised, controlled trial in patients with benign prostatic ?obstruction? (symptomatic BPH). Br J Urol. 1995; 76: 325-36.
15. Lepor H; for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia. Placebo-controlled, double- blind extension of phase III trial. Urology. 1998; 51: 901-6.
16. Chapple CR, Wyndaele JJ, Nordling J et al. Tamsulosin, the first prostate-selective ?1A-adrenoceptor antagonist: a meta-analysis of two randomised, placebo-controlled, multi-centre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 1996; 29: 155-67.
17. Michel MC, Gru?bbel B, Taguchi K et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha-1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996; 16: 21-8.
18. Schwinn DA, Michelotti GA. ?1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the ?1D subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000; 85(suppl 2): 6-11.
19. Romic I, Kiss T, Kisbenedek L et al. Tamsulosin drug ratio in prostate versus free fraction in plasma supports pharmacokinetic (PK) contribution to its uroselectivity. J Urol. 2003; 169(4 suppl): 288 [Abstract 1118].
20. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin. An update of its role in the management of lower urinary tract symptoms. Drugs. 2002; 62: 135-67.
21. Michel MC, Korstanje C, Krauwinkel W. Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. Eur Urol Suppl. 2005; 4(2): 9-14.
22. Michel MC, Korstanje C, Krauwinkel W et al. Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation. Eur Urol Suppl. 2005; 4(2): 53-60.